Evidence map›Paper›PMID 30573690›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.

Theodore S Nowicki, Beata Berent-Maoz, Gardenia Cheung-Lau, Rong Rong Huang, Xiaoyan Wang, Jennifer Tsoi, Paula Kaplan-Lefko, Paula Cabrera, Justin Tran, Jia Pang and 11 more

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 67 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01697527 phase2active not recruitingnot on this map

Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) After a Nonmyeloablative Conditioning Regimen, With Administration of NY-ESO-1157-165 Pulsed Dendritic Cells and Interleukin-2, in Patients With Advanced Malignancies

TypeinterventionalSponsorJonsson Comprehensive Cancer CenterRan2012 to 2027Enrolled6ConditionsMalignant NeoplasmArmsaldesleukin, fludarabine phosphate, cyclophosphamide, laboratory biomarker analysis, NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
NCT02070406 phase1terminatednot on this map

NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With CTLA4 Blockade

TypeinterventionalSponsorJonsson Comprehensive Cancer CenterRan2014 to 2018Enrolled4ConditionsUnspecified Adult Solid Tumor, Protocol SpecificArmscyclophosphamide, fludarabine phosphate, NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL, dendritic cell vaccine therapy, aldesleukin
3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Engineering adoptive cell therapy for solid tumors.Medical oncology (Northwood, London, England) · 2025
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Novel H-2DJournal for immunotherapy of cancer · 2024
    Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Theodore S NowickiDivision of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, California.
Beata Berent-MaozDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.
Gardenia Cheung-LauDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.
Rong Rong HuangDepartment of Pathology, University of California Los Angeles, Los Angeles, California.
Xiaoyan WangDepartment of General Internal Medicine and Health Services Research, University of California Los Angeles, Los Angeles, California.
Jennifer TsoiDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.
Paula Kaplan-LefkoDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.
Paula CabreraDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.
Justin TranDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.
Jia PangDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.
Mignonette MacabaliDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.
Ivan Perez GarcilazoDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.
Ignacio Baselga CarreteroDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.
Anusha KalbasiDivision of Molecular and Cellular Oncology, Department of Radiation Oncology, University of California Los Angeles, Los Angeles, California.
Alistair J CochranDepartment of Pathology, University of California Los Angeles, Los Angeles, California.
Catherine S GrassoDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.
Siwen Hu-LieskovanDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.
Bartosz ChmielowskiDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.
Begoña Comin-AnduixJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.
Arun SinghDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California. asingh@mednet.ucla.edu aribas@mednet.ucla.edu.
Antoni RibasDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California. asingh@mednet.ucla.edu aribas@mednet.ucla.edu.
University of California, Los Angeles · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Pediatric Scientist Development Program (PSDP) [K12]K12HD000850 · NICHD · YALE UNIVERSITY · PI Sallie R. Permar · 1987 to 2026
$44.1M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CUMBERLAND, WILLIAM GLEN · 1991 to 2018
$39.9M
Next Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4M
UCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3M
TARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RIBAS, ANTONI · 2013 to 2017
$8.4M
NCI NIH HHS P01 CA168585NCI NIH HHS P30 CA016042NCI NIH HHS R35 CA197633NCI NIH HHS T32 CA009120NIAID NIH HHS P30 AI028697NICHD NIH HHS K12 HD000850
6 · The paper itself

Abstract

purposeTransgenic adoptive cell therapy (ACT) targeting the tumor antigen NY-ESO-1 can be effective for the treatment of sarcoma and melanoma. Preclinical models have shown that this therapy can be improved with the addition of dendritic cell (DC) vaccination and immune checkpoint blockade. We studied the safety, feasibility, and antitumor efficacy of transgenic ACT with DC vaccination, with and without CTLA-4 blockade with ipilimumab. PATIENTS AND

methodsFreshly prepared autologous NY-ESO-1-specific T-cell receptor (TCR) transgenic lymphocytes were adoptively transferred together with NY-ESO-1 peptide-pulsed DC vaccination in HLA-A2.1-positive subjects alone (ESO, NCT02070406) or with ipilimumab (INY, NCT01697527) in patients with advanced sarcoma or melanoma.

resultsSix patients were enrolled in the ESO cohort, and four were enrolled in the INY cohort. Four out of six patients treated per ESO (66%), and two out of four patients treated per INY (50%) displayed evidence of tumor regression. Peripheral blood reconstitution with NY-ESO-1-specific T cells peaked within 2 weeks of ACT, indicating rapid

conclusionsACT of fresh NY-ESO-1 transgenic T cells prepared via a short

Indexed as

Adoptive TransferAdultAnimalsAntineoplastic Agents, ImmunologicalCancer VaccinesCell Line, TumorCombined Modality TherapyCTLA-4 AntigenDendritic CellsFemaleGene Knock-In TechniquesHumansImmunotherapyIpilimumabLymphocytesMaleAntineoplastic Agents, ImmunologicalCancer VaccinesCTLA-4 AntigenCTLA4 protein, humanIpilimumabReceptors, Antigen, T-Cell

Identifiers

PMID30573690
PMCPMC6445780
OpenAlexW2905107741

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.